

2

DTIC FILE COPY

AD _____

AD-A185 914

STUDIES OF ALTERED RESPONSE TO INFECTION INDUCED BY SEVERE INJURY

ANNUAL REPORT

CAROL L. MILLER, PH.D.

March 1, 1987
(24 January 1986 - 23 January 1987)

DTIC
SELECTED
OCT 09 1987
S D
D

Supported by

U.S. Army Medical Research and Development Command
Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD 17-86-C-⁶⁰⁹⁷~~6091~~

University of Massachusetts
Department of Surgery
55 Lake Avenue, No.
Worcester, Massachusetts 01655

Approved for public release: distribution unlimited

The findings in this report are not to be construed as an official Department of Army position unless so designated by other authorized documents.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1a. REPORT SECURITY CLASSIFICATION Unclassified		1b. RESTRICTIVE MARKINGS A185914	
2a. SECURITY CLASSIFICATION AUTHORITY		3. DISTRIBUTION / AVAILABILITY OF REPORT Approved for public release; Distribution unlimited	
2b. DECLASSIFICATION / DOWNGRADING SCHEDULE			
4. PERFORMING ORGANIZATION REPORT NUMBER(S)		5. MONITORING ORGANIZATION REPORT NUMBER(S)	
6a. NAME OF PERFORMING ORGANIZATION Univ. of Massachusetts	6b. OFFICE SYMBOL (if applicable)	7a. NAME OF MONITORING ORGANIZATION	
6c. ADDRESS (City, State, and ZIP Code) Dept. of Surgery 55 Lake Avenue, No. Worcester, MA 01685		7b. ADDRESS (City, State, and ZIP Code)	
8a. NAME OF FUNDING / SPONSORING ORGANIZATION USAMRDC	8b. OFFICE SYMBOL (if applicable)	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD 17-86-C-6097	
8c. ADDRESS (City, State, and ZIP Code) Ft. Detrick Frederick, MD 21701-5012		10. SOURCE OF FUNDING NUMBERS	
		PROGRAM ELEMENT NO. 62772A	PROJECT NO 3S162 772A874
11. TITLE (Include Security Classification) Studies of altered response to infection induced by severe injury			
12. PERSONAL AUTHOR(S) Carol L. Miller, Ph.D.			
13a. TYPE OF REPORT Annual	13b. TIME COVERED FROM 1/24/86 TO 1/23/87	14. DATE OF REPORT (Year, Month, Day) 87 March 1	15. PAGE COUNT 25
16. SUPPLEMENTARY NOTATION			
17. COSATI CODES		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	Trauma patients, monocyte functions, PGE ₂ , monocyte subsets, Immunosuppression	
06	13		
06	05		
19. ABSTRACT (Continue on reverse if necessary and identify by block number) This year has greatly expanded our understanding of the development of immuno-incompetence in trauma patients and suggests the usefulness of clinical trials with PGE ₂ inhibitors. Our preliminary data on the relationship between an early (3 days post injury) shift in identifiable MØ subset ratio and the development of immunoincompetence have importance to the rapid detection of patient immuno-incompetence. If we can firmly establish that measurement of the ratio alone is sufficient to predict increased risk of sepsis, then this assessment has potential use in military care of the wounded. A simple assay for determining the ratio of Fc ⁺ MØ to Fc ⁻ MØ is easily developed. Such an assay would only require drawing a very small blood sample. The peripheral blood could be rapidly segregated on Lymphoprep or other commercial preparations, then MØ isolated by adherence to prepared Akerman Douglas plates for 2 hrs., then labeled with anti Fc fluorescent labeled antibody. Counting the number of florescently labeled MØ in a 100 MØ total could then be performed in a very short time resulting in a relevant clinical monitoring tool.			
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT <input type="checkbox"/> UNCLASSIFIED/UNLIMITED <input checked="" type="checkbox"/> SAME AS RPT <input type="checkbox"/> DTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION Unclassified	
22a. NAME OF RESPONSIBLE INDIVIDUAL Judy Pawlus		22b. TELEPHONE (Include Area Code) 01-663-7325	22c. OFFICE SYMBOL SGRD-RMI-S

SUMMARY

This year has greatly expanded our understanding of the development of immuno-incompetence in trauma patients and suggests the usefulness of clinical trials with PGE₂ inhibitors. Our preliminary data on the relationship between an early (3 days post injury) shift in identifiable MØ subset ratio and the development of immuno-incompetence have importance to the rapid detection of patient immuno-incompetence. If we can firmly establish that measurement of the ratio alone is sufficient to predict increased risk of sepsis, then this assessment has potential use in military care of the wounded. A simple assay for determining the ratio of Fc⁺ MØ to Fc⁻ MØ is easily developed. Such an assay would only require drawing a very small blood sample. The peripheral blood could be rapidly segregated on Lymphoprep or other commercial preparations, then MØ isolated by adherence to prepared Akerman Douglas plates for 2 hrs., then labeled with anti Fc florescent labeled antibody. Counting the number of florescently labeled MØ in a 100 MØ total could then be performed in a very short time resulting in a relevant clinical monitoring tool.

Accession For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	



FOREWORD

In conducting the research described in this report, the investigator adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources Commission of Life Sciences, National Research Council (NIH Publication No. 86-23, Revised 1985).

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement of approval of the products or services of these organizations.

For the protection of human subjects, the investigator has adhered to policies of applicable Federal Law 45CFR46.

TABLE OF CONTENTS

	<u>Page No.</u>
Summary.	iii
Foreword.	iv
Introduction	1
Methods.	2
Results and Discussion	4
References	9
Distribution List.	20

LIST OF TABLES

TABLE 1 - Correlation MØ and T Cell Depression and Clinical Outcome.	10
TABLE 2 - Effect of Patient T _s Cells on MØ Function ^a	11
TABLE 3 - Effect of Patient T Cells on MØ Function	12
TABLE 4 - Effect of MDP ^A on Normal or Patient MØ Function.	13
TABLE 5 - Change on MØ FC ⁺ /Fc ⁻ Subset Ratios Over Time Post Injury	14
TABLE 6 - PA Activity of MØ Subsets after Interaction with Patient T Cells.	15
TABLE 7 - Fc ⁺ MØ Subset Contains the MØ Which Are Producing Leukocyte Pyrogen (LP)	16

LIST OF FIGURES

FIG. 1 - Effect of Patients' T Cells ^A on Normal MØ Functions.	17
FIG. 2 - Increase in Fc ⁺ MØ Population in Immunoincompetent Patients ^A	18
FIG. 3 - Fc ⁺ MØ Subset ^A Contains the PGE ₂ Producing Cells	19

Introduction

The goals of this research are (1) to delineate the role of suppressor T cells and inhibitory monocytes (MØ) in mediating the immunosuppression that follows severe injury, (2) to develop and improve assays for assessment of macrophage function, (3) to investigate the relationship between immunosuppression and post-trauma alterations in MØ subsets, and to investigate prophylactic modalities for reversing immunosuppression.

In pursuing goal one of this contract period, we have demonstrated that trauma induced suppressor T cells (T_s) can depress monocyte function and that at least some of the T_s mediate immunosuppression by stimulating monocytes to produce elevated levels of prostaglandin E_2 (PGE_2). In pursuing goal two, we have concentrated on trying to associate a change in MØ function with a change in MØ phenotype. We have shown that elevation of MØ PGE_2 production appears to correlate with the shift toward a MØ subset that can be identified by its expression of a high affinity receptor for the crystalline fragment of Immunoglobulin G (i.e., Fc^+). If it is possible to develop a phenotype profile of a defective MØ, then it would no longer be necessary to do functional assays on patients' blood. Instead, a small quantity of blood could be drawn, the MØ rapidly isolated (2 hours) and stained with fluorescent antibodies which were directed against the surface markers known to identify a particular subset. The increased appearance of this subset could then be enumerated by a simple counting technique allowing quick detection of the onset of immunoincompetence at far forward locations. It is for this reason that we have pursued goal three. We have demonstrated that there is an increase in the numbers of the Fc^+ MØ subset and that this increase correlates both to elevation of PGE_2 production and poor clinical outcome. Finally, in testing of possible new prophylactic

therapies, we have been initially stymied by the failure to have our burned guinea pig model approved by the Animal Research Committee. However, after making several changes in the protocol, we feel that approval should be granted in the next contract year. We have, however, examined the effect of a monocyte stimulator (muramyl dipeptide) on patient MØ function in vitro. Our results suggest that this agent increases MØ PGE₂ production and is contra-indicated in patients who have already undergone a shift in their MØ subset ratios toward a larger proportion of PGE₂ producers. There had been some reports in the literature suggesting the use of MDP as an immunopotentiator.

In summary, this has been a highly productive year in which we have made progress on many of the goals of the five year contract. Our most significant finding is probably the relationship between elevation of immunocompromised patient MØ PGE₂ production and a shift in the patient MØ subset ratios.

Methods

The Plasminogen Activator (PA) assay is performed as previously described (1). The procoagulant assay and the lysozyme assay are also performed as previously described (1-2). The assay for suppression of MØ PA activity is performed by isolating the MØ as described (1), then recombining either 2×10^6 normal or 2×10^6 patient MØ with equal numbers (2×10^6) of the patients E-rosetted T cells. The mixed populations are co-cultured for 48 hours in Iscove's supplemented with 8% FCS and media supplements as described (1). In most assays, the normal and patient MØ are collected at day 1-5 post injury and cultured in supplemented Iscove's for 3-4 days. The patient T cells collected at 5-9 days post injury are co-cultured with the normal or patient MØ collected 3-4 days earlier.

MØ PGE₂ is measured with a standard RIA as previously described (3). Leukocyte pyrogen is assessed in a modification of the Bodell assay (4). In this modification, 250 gm Balb/c mice are pre-warmed to 37°, and their baseline temperatures determined over a 20-minute period. The mice then receive a 0.20 ml IV injection of supernates collected from the patients or normal MØ cultures.

The elevation of the mice temperatures is recorded over a 50-minute period with a Yellow Springs Thermoprobe and chart recorder. A media control is also always included.

The sensitivity of MØ to Muramyl Dipeptide is assessed by culturing isolated MØ with 20 µg/ml of MDP for 48 hours in a protocol identical to that we have previously used in experiments with peptidoglycan (5). The PA, PGE₂, Lysozyme, and procoagulant activities of the patient and normal MØ are compared in the presence and absence of MDP. The measurement of the MØ LP levels in the MDP stimulated MØ culture supernates has presented special problems. The correct control is media + MDP. However, both this control and the normal MØ supernates contain residual MDP which in and of itself causes elevation of the mice temperatures. Although the kinetics of this MDP induced pyrogen activity are different than that of LP (LP peak 20 min., MDP peak > 70 min.), the overlap complicated data interpretation.

As previously reported in our quarterly, we now use a protocol whereby the mice are made MDP tolerant by 3 days of injection of increasing MDP doses. When the animals are no longer responsive to MDP, they are used to assess the LP activity of the MDP containing MØ supernates. Using this technique, we have derived significant information on MØ LP stimulation by MDP.

Three methods are used to generate subsets of MØ. All three are rosetting based protocols. In order to isolate MØ positive for the high affinity Fc receptor for IgG, we rosette with anti-Rh antibody coated human erythrocytes using the method of Zembala et al (6). The method for rosetting a population of DQ⁺ MØ involves CrCl linking of anti DQ monoclonal antibody to Ox red cells following the method of Mills et al (7). The third method of generating MØ subsets involves treatment of MØ with anti-CR (C3b, C4b receptors) antibody and rosetting the CR negative MØ using anti sheep red blood cell coated erythrocytes with complement compounds 1, 4, 2, 3 on their surface (8).

Results and Discussion

In the period covered by the first year of contract No. DAMD17-86-C-6091, several goals have been attained. Thirty-one patients have been nominated this year. The patients included 19 burn and 11 trauma patients.

Of these patients, twelve were studied the first four months, eight the next three months, seven the third three months, and four the last two months of the year. Of these patients, three burn patients and two trauma patients have succumbed to fatal sepsis. The small number of trauma patients studied is a result of our consistent exclusion of head trauma. Most of the patients are admitted to the trauma center with significant head trauma. Consequently, in the coming year, patients with significant trauma and moderate head trauma will be studied as separate subsets of our trauma patient group.

As we have previously shown, the trauma patients who experienced immunodepression had reduced monocyte (MØ) plasminogen activator (PA) activity with simultaneously elevated MØ PGE₂ and leukocyte pyrogen (LP). As illustrated in Table 1, there is a consistent correlation between (1) MØ PA depression and (2) depression of phytohemagglutinin (PHA) induced T cell melogenesis concomitant with (3) PGE₂ elevation of MØ prostaglandin E₂ (PGE₂) levels and (4) poor prognosis. As can be seen, there is little change in MØ PGE₂ in either trauma or burn patients who experience no immunodepression or septic complications. The data showing PGE₂ to be correlated to immunodepression has lead us to re-examine the excessive T lymphocytic suppressor cell activity in immunocompromised trauma patients. We examined the affect of patients' isolated T cells on monocyte responses. Both the patients own and normal monocytes were assessed. The patients' MØ are isolated at day one post injury, then cultured for three days in Iscove's medium. Normal controls are similarly cultured for three days. On day 4-5 post injury, the patients' T cells are isolated and added to both patient and normal cultures. After a further two-day incubation, the response of the normal and patients' MØ without added T cells are compared to the patient and normal cultures which have been incubated two days with

patients' T cells. The patients' T cells collected at 3-7 days post injury consistently suppressed the patients' own MØ plasminogen activator responses, as can be seen in Table 2, Fig. 1. Patients' T cells collected at greater than day 6 post injury consistently suppressed normal MØ PA responses. However, the suppressive activity for normal MØ PA production of patient T cells collected earlier in the post trauma course was variable. These data suggest some genetic restriction on the action of T_s collected at an earlier post injury period. The depression of MØ PA by patient T cells does not appear to result from protein synthesis depression or from cytotoxicity. As also illustrated in Table 2, Fig. 1, and Table 3, the PGE_2 production and leukocyte pyrogen (LP) activity of these immunosuppressed patient MØ are augmented simultaneously to depression of MØ PA activity.

One possible mechanism by which patient T cells could non-specifically suppress normal MØ function is by increasing the MØ PGE_2 levels. In previous years, we have reported an overall increase in PGE_2 production in patients who experienced immunoincompetence. In our recent experiments, we have examined the ability of patients' T_s to increase PGE_2 production. As illustrated in Table 2, Fig. 1, the patient T cells isolated at day 1 post injury are not inhibitory to the PA response nor do they exhibit increased PGE_2 production. However, T cells from the same patient collected at 6-13 days post injury suppressed normal MØ PA, increased MØ PGE_2 levels, and increased normal MØ leukocyte pyrogen (LP) activity. These data imply that increase in MØ PGE_2 production may significantly contribute to immunosuppression of trauma patients. In addition, at least one of the mechanisms for post trauma increases in MØ PGE_2 is the action of T_s on MØ. Increased PGE_2 levels will depress MØ PA production and MØ antigen presenting capacity thereby increasing T_s generation.

As already illustrated, patients' MØ populations exhibit much higher PGE_2 levels than can be induced in normal MØ populations. This apparent increased sensitivity to PGE_2 induction would result if trauma induced (via complement split products, fibrin degradation products or leukocyte mediators) a shift in

the proportion or ratio of the MØ subset that produces PGE₂. Previous investigators have indicated that the MØ population is functionally heterogenous and that this functional heterogeneity is associated with certain MØ subsets. Alternately, trauma could increase the ability of each individual MØ to produce PGE₂.

We have examined the stimulation capacity of Muramyl Dipeptide (MDP) on patient and normal MØ to detect any post-trauma change in MØ responsiveness to bacterial stimuli. MDP is a potent PGE₂ secretagogue and we, and others, have found that it also depresses MØ PA activity. As can be seen in Table 4, 20 µg/ml of MDP stimulates maximal PGE₂ activity in the range of 50,000 pg for both normal and patient day 1 MØ. Increasing the dose of MDP to 30 µg/ml failed to increase the level of PGE₂ above this range. In striking contrast, the patient MØ collected at > Day 6 post were continually producing high levels of PGE₂, and when stimulated with MDP, increased these levels by 2 to 3 fold. The MØ PA responses of these patients already appeared to be maximally suppressed and did not additionally decrease their PA and responses upon MDP stimulation. These data indicate either a post-trauma increase in a PGE₂ producing subset or an increased capacity for PGE₂ production in all MØ.

We examined the subset ratios of patients MØ populations using the MØ subset with a high affinity receptor for IgG2 (Fc⁺). This Fc⁺ subset has been previously suggested to contain the inhibitory MØ population (6). We, therefore, examined the PGE₂ production and Fc⁺ subset proportions in immunosuppressed trauma patients. As can be seen in Figures 2 and 3, immunodepressed patients had a dramatic increase in the proportion of the Fc⁺ MØ which coincided with an increase in their PGE₂ activity. The Fc⁺ MØ were the primary, if not the sole, MØ producers of PGE₂. The normal MØ and immunocompetent patient MØ populations contained approximately 40% high affinity Fc⁺ MØ and 60% Fc⁻ MØ after isolation on Ackerman Douglas Flasks. We have now examined a number of patients over time post injury. Those patients who survived multiple septic episodes and regained immunocompetence showed a return

to normal Fc^+/Fc^- MØ ratio levels (Table 5). Trauma patients with normal PA responses had normal Fc^+/Fc^- MØ ratios. Interestingly, patients with depressed MØ PA had normal PA responses when only their isolated Fc^- monocytes were assessed in the absence of the Fc^+ subset. Similarly, the patients late T_s were unable to suppress either the patients Fc^- or normal Fc^- MØ PA responses. Only Fc^+ responses were suppressed (Table 6). These data support the idea that some of the T_s suppression mechanism may be partially a result of increasing MØ PGE_2 activity.

We have also examined the leukocyte pyrogen (LP) responses of the Fc^+ and Fc^- subsets and found that LP activity is confined primarily to the Fc^+ MØ subset (Table 7). Addition of immunosuppressed patient T_s to normal or day 1 post injury patient MØ was found to increase the MØ LP activity as well as depress the MØ PA activity.

In summary, these data further support our hypothesis that a shift in the trauma patient Fc^+ to Fc^- MØ ratio increases overall patient PGE_2 production. Furthermore, excessive T_s generation may also contribute to elevating MØ PGE_2 levels and development of immunoincompetence. Several questions on the mechanism by which trauma could mediate immunosuppression are currently being explored. It is possible that immunosuppressive patient Fc^- MØ are altered so that they can respond to MDP with PGE_2 production. We have already shown that normal Fc^- monocytes can not be stimulated by MDP to produce PGE_2 or LP. However, we do not as yet have data indicating that patient Fc^- MØ do not respond to MDP stimulation by increasing their PGE_2 or LP output. It also must be noted that the MØ subset we are calling Fc^- is not, in fact, devoid of Fc receptors. The anti RH antibody consists primarily of IgG2. Human monocytes have two receptors for IgG, a "high affinity" receptor with a preference for IgG2, and a "low affinity" receptor with a preference for IgG₁. When we utilized a specific anti low affinity Fc receptor antibody, we found that most (if not all) MØ have the low affinity Fc receptor, but only a subset express the high affinity. Consequently, the Fc^+ population we are describing in actuality

is the high affinity positive population. Nevertheless, our data show that this high affinity positive MØ subset is increased at the expense of the low affinity (Fc^-) subset in immunocompromised trauma patients. This high affinity Fc^+ MØ subset is enriched for both LP and PGE_2 producers but not for PA producers. The result of this shift in MØ subset Fc^+/Fc^- ratio is that patients who develop immunoincompetence show increased PGE_2 production and respond to bacterial stimuli (MDP) with a greater production of PGE_2 than normal individuals' MØ. Furthermore, T cells from immunoincompetent patients can depress facilitory MØ functions (i.e. PA) and increase MØ PGE_2 levels thereby further perpetuating the immunosuppressive cycle.

This year has greatly expanded our understanding of the development of immuno-incompetence in trauma patients and suggests the usefulness of clinical trials with PGE_2 inhibitors. In addition, these preliminary data are on the relationship between an early (3 days post injury) shift in identifiable MØ subset ratio and the development of immunoincompetence have importance to the rapid detection of patient immunoincompetence. If we can firmly establish that measurement of the ratio alone is sufficient to predict increased risk of sepsis, then this assessment has potential for army use. A simple assay for determining the ratio of Fc^+ MØ to Fc^- MØ is easily developed. Such an assay would only require drawing a very small blood sample. The peripheral blood could be rapidly segregated on Lymphoprep or other commercial preparations, then MØ isolated by adherence to prepared Akerman Douglas plates for 2 hrs., then labeled with anti Fc florescent labeled antibody. Counting the number of florescently labeled MØ in a 100 MØ total could then be performed in a very short time resulting in a relevant clinical monitoring tool.

References

1. Miller CL, Graziano CJ, Lim RC: Human monocyte plasminogen activator production: correlation to altered MØ-T lymphocyte interaction. *J. Immunol.* 1982. 126, 2194-2200.
2. Miller CL, Lim RC: Dextran as a modulator of immune and coagulation activities in trauma patients. *J. Surg. Res.* 1985. 39, 183-191.
3. Fink MP, Caveda EO, Gardiner WM, Fiddian-Green RG: Increased ex vivo synthesis of prostaglandin E₂ by gastric tissue after hemorrhage in rats. *Am. J. Surg.* 1987. 153, 139-143.
4. Bodel P, Miller H. Pyrogen from mouse macrophages causes fever in mice. *Proc. Soc. Exp. Bio.* 1976. 151, 93.
5. Gold MR, Miller CL, Mishell RI: Soluble non-cross-linked peptidoglycan polymers stimulate monocyte-macrophage inflammatory functions. *Infect. Immunol.* 1985, 49, 731-741.
6. Zembala M, Uracz W, Ruggiero I, Mytar B, Pryjma J: Isolation and functional characteristics of FcR^f and FcR⁻ human monocyte subsets. *J. Immunol.* 1984. 133, 1293-1299.
7. Mills K, Armitage R, Worman C: An indirect rosette technique for the identification and separation of human lymphocyte populations by monoclonal antibodies. A comparison with immunofluorescence methods. *Immunol. Lett.* 1983. 6, 241.
8. Dobson NJ, Lambris JD, Ross GD: Characteristics of isolated erythrocyte complement receptor type one (CR₁, C4b-C3b receptor) and CR₁-specific antibodies. *J. Immunol.* 1981, 126, 693-698.

TABLE 1

Correlation MØ and T Cell Depression and Clinical Outcome

Pt	Injury	Δ PHA% ^a	PA(01-13) ^b	Δ PGE ₂ x 10 ⁻³ pg ^c	Outcome
Ja	Trauma	55	41.8 → 14.1	1.9 → 15.4	Multiple septic episodes
Sw	Trauma	- 90	26.8 → 8.6	1.5 → 12.8	Fatal sepsis
Ch	Trauma	- 20	34.1 → 22.0	8.4 → 6.8	No complications
Br	Trauma	- 15	18.0 → 22.2	4.3 → 1.6	No complications
Pr	Trauma	- 20	32.9 → 24.4	12.3 → 12.3	No complications
Mu	Burn	- 87	48.8 → 7.2	1.6 → 23.6	Fatal sepsis
Ke	Burn	- 59	32.1 → 12.9	2.7 → 11.3	Multiple septic episodes
Ar	Burn	- 82	45.4 → 19.1	5.9 → 14.2	Multiple septic episodes
Be	Burn	- 79	41.6 → 15.0	5.3 → 12.5	Fatal sepsis
Ho	Burn	- 80	39.2 → 8.2	3.3 → 13.9	Multiple septic episodes
Cr	Burn	- 78	31.8 → 14.7	2.6 → 11.1	Fatal sepsis
Gh	Burn	+ 30	44.2 → 39.9	5.8 → 5.0	No complications
Jo	Burn	+100	26.1 → 21.5	7.0 → 8.8	One infectious episode
Ro	Burn	+ 12	32.4 → 27.6	2.8 → 2.6	No complications
Nu	Burn	- 20	25.0 → 18.9	6.7 → 9.9	No complications

- a. Maximum change at 4-13 days post injury in mitogen induced proliferation of 2×10^5 peripheral blood mononuclear cells to 0.2 mg PHA
- b. Maximum change in MØ plasminogen activator (PA) activity from initial response to most depressed in the first 13 days post injury. PA activity measured in % plasmin specific fibrinolysis
- c. Maximum prostaglandin E₂ production in first 13 post injury days measured as picograms per 10^6 recovered MØ ($\times 10^{-3}$)

TABLE 2

EFFECT OF PT T_S-CELLS ON MØ FUNCTION^a

<u>PGE₂</u>	<u>pg/10⁶MØ</u> ^b	<u>PA</u>
Norm MØ + D1 PT T-Cells ^c	9,025	30.4
Norm MØ	13,544	27.1
Norm MØ + D>6 T-Cell	45,451	16.5
Norm MØ	22,610	34.5

- a. T lymphocytes were isolated from patient mononuclear preparations by E rosetting of MØ depleted populations.
- b. PGE₂ in picograms per 10⁶ recovered MØ.
- c. 2 x 10⁶ MØ were cocultured 2 days with 2 x 10⁶ patient (pt) T lymphocytes collected at day 1 post-injury (D1).

Table 3EFFECT OF PATIENT T CELLS ON MØ FUNCTION

CELLS	LP Δ temp ^a		PA% ^b	
	Exp 112	Exp 130	Exp 112	Exp 130
Norm MØ	.3	.15	59.5	52.6
Norm MØ + Pt T Cell ^c	.35	.20	37.7	22.3
Pt MØ	.35	.65	21.5	49.9
Pt MØ + Pt T Cell ^d	.75	.85	10.5	13.9

- a. Leukocyte pyrogen (LP) was assessed as change in temperature (Δ temp) of mice injected with 0.3 ml MØ supernate
- b. MØ production of plasminogen activator (PA) is measured in percent specific fibrinolysis
- c. 2×10^6 normal individual's MØ were cocultured for 2 days with 2×10^6 patient (Pt) T lymphocytes
- d. 2×10^6 patient MØ isolated at day 1-3 post-injury and maintained in culture were then cocultured for 2 days with the Pt T cells collected 4-6 days post-injury

Table 4

EFFECT OF MDP^A ON NORMAL OR PATIENT Mφ FUNCTION

Mo	PGE ₂ ^b	PA ^c
Norm	16 944 ± 6 717	31.4 ± 7.4
Norm + MDP	54 387 ± 23 030	15.2 ± 3.8
D1 Pt	19 759 ± 7 295	33.5 ± 12.1
D1 Pt + MDP	49 049 ± 22 529	13.8 ± 4.2
D>6 Pt	37 940 ± 11 606	14.4 ± 4.1
D>6 Pt + MDP	91 851 ± 20 951	14.0 ± 1.6

- A. 2×10^6 Mφ CULTURED FOR 2 DAYS WITH 20 μG/ML OF MURAMYL DIPEPTIDE (MDP)
- B. PROSTAGLANDIN E₂ PRODUCTION IN PICOGRAMS PER 10^6 RECOVERED Mφ
- C. PLASMINOGEN ACTIVATOR ACTIVITY IN % SPECIFIC FIBRINOLYSIS.

TABLE 5

Change on MØ Fc⁺/Fc⁻ subset ratios over time post injury

	<u>% Fc⁺/Fc⁻</u>		<u>Fc⁺</u>	<u>Fc⁻</u>
PtT day 15	75/25		38±6	62±6
day 21	66/34	X Normal = 14		
day 29	80/20			
day 37	58/42			
day 47	48/52			
day 52	47/53			
PtR day 9	62/38			
day 16	32/68			

Table 6

PA Activity of MØ subsets after interaction with patient T cells


	Unsep ^a	Fc ⁺ ^b	Fc ⁻ ^c	Unsep + T ^d	Fc ⁻ +T	Fc ⁺ +T
Pt	43.8	32.9	59.3	-	-	-
Nor	49.6	29.4	41.6	-	-	-
Pt	34.1	38.3	41.9	-	-	-
Nor	26.1	27.0	41.8	-	-	-
Pt	10.9	8.2	19.7	-	-	-
Nor	19.3	11.5	29.5	-	-	-
Pt	19.4	22.6	31.5	-	-	25.2
Nor	21.7	22.4	33.5	-	29	30.1
Pt	31.7	20.6	46.4	18.6	29.3	6.9
Nor	26.5	21.4	35.4	-	-	19.2

- a. Plasmin specific fibrinolysis of 5×10^5 unseparated (Unsep) heterogenous MØ from either patients (Pt) or Normals (Nor)
- b. 5×10^5 MØ⁻ with high affinity receptors for IgG rosetted with anti-RH antibody coated human erythrocytes
- c. 5×10^5 MØ depletion of Fc⁺ rosetting cells
- d. 5×10^5 MØ derived from cultures incubated with Pt T lymphocytes collected at 3-4 days after the MØ

Fc⁺ MØ SUBSET CONTAINS THE MØ WHICH ARE PRODUCING
 LEUKOCYTE PYROGEN (LP)

<u>MØ Pop^A</u>	<u>PATIENT</u>		<u>NORMAL</u>	
	<u>PGE₂</u>	<u>LP^B</u>	<u>PGE₂</u>	<u>LP</u>
Fc ⁺	12.665	.55	4.058	.25
Fc ⁻	1.484	0	847	0


- A. MØ POPULATIONS (POP) WERE SELECTED FOR Fc RECEPTOR BY ROSSETTING WITH ANTI RH COATED RED CELLS.
- B. LEUKOCYTE PYROGEN WAS ASSAYED AS CHANGE IN TEMPERATURE (ΔTEMP) OF MICE INJECTED WITH 0.3 ML OF MØ SUPERNATE.



- A. T LYMPHOCYTES WERE ISOLATED FROM PATIENT MONONUCLEAR PREPARATIONS BY E ROSETTING OF Mφ DEPLETED POPULATIONS
- B. 2x10⁶ NORMAL Mφ WERE COCULTURED FOR 2 DAYS WITH 2x10⁶ PATIENT T LYMPHOCYTES

FIG. 1

EFFECT OF PATIENTS' T CELLS^A ON NORMAL Mφ FUNCTIONS



- A. ISOLATION OF PATIENT Fc⁺ AND Fc⁻ MO POPULATIONS PERFORMED BY ROSETTING WITH ANTI-RH ANTIBODY COATED HUMAN ERYTHROCYTES
- B. NON ROSETTING POPULATION
- C. PERCENT OF THE TOTAL POPULATION ROSETTING WITH ANTI-RH COATED ERYTHROCYTES

FIG. 2

INCREASE IN Fc⁺ MO POPULATION IN IMMUNOINCOMPETENT PATIENTS^A




FIG. 3

Fc⁺ Mφ SUBSET^A CONTAINS THE PGE₂ PRODUCING CELLS

DISTRIBUTION LIST

4 copies	Commander Letterman Army Institute of Research (LAIR), Bldg. 1110 ATTN: SGRD-ULZ-RC Presidio of San Francisco, CA 94129-6815
1 copy	Commander US Army Medical Research and Development Command ATTN: SGRD-RMI-S Fort Detrick, Frederick, Maryland 21701-5012
2 copies	Defense Technical Information Center (DTIC) ATTN: DTIC-DDAC Cameron Station Alexandria, VA 22304-6145
1 copy	Dean School of Medicine Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20814-4799
1 copy	Commandant Academy of Health Sciences, US Army ATTN: AHS-CDM Fort Sam Houston, TX 78234-6100

END

12-87

DTIC